Centrilobular emphysema ranges from a barely noticeable incidental finding on a CT scan to a life-threatening condition, and the grade at diagnosis is one of the strongest predictors of how things will go. In a large study of over 3,000 people with COPD, even mild centrilobular emphysema raised the risk of death compared with having no visible emphysema, and that risk climbed steeply with each worsening grade. The seriousness depends heavily on how far the disease has progressed, whether you are still smoking, and what other complications have developed alongside the lung damage.
What Centrilobular Emphysema Actually Is
Centrilobular emphysema is a specific pattern of lung destruction that starts in the center of the lung’s smallest functional units, called lobules. The damage begins around the tiny airways deep in the lung, known as respiratory bronchioles, and works its way outward. It preferentially hits the upper lobes of the lungs, which tend to be more severely and frequently affected than the lower lobes.1PubMed Central. The centrilobular form of hypertrophic emphysema and its relation to chronic bronchitis This upper-lobe pattern is one of the features that distinguishes it from other types of emphysema on imaging.
The destruction is driven by an imbalance between enzymes that break down tissue and the molecules that normally keep those enzymes in check. Cigarette smoke is the overwhelming trigger. Animal studies show that smoke exposure tips the balance toward unchecked protease activity in the small airways, leading to breakdown of the structural scaffolding that holds the air sacs open.2PubMed. Mechanisms of cigarette smoke-induced COPD: insights from animal models Research has identified a specific protective molecule in the small airways, a serine protease inhibitor called LEKTI, whose suppression under chronic smoke exposure accelerates the tissue destruction, barrier dysfunction, and loss of the tethering structures that attach airways to surrounding lung tissue.3PubMed. Serine Protease Imbalance in the Small Airways and Development of Centrilobular Emphysema in Chronic Obstructive Pulmonary Disease Once those air sacs are destroyed, they do not grow back. The damage is permanent.
Why the Grade on Your CT Report Matters So Much
When a radiologist reads your chest CT, they typically classify emphysema by visual appearance into categories like trace, mild centrilobular, moderate centrilobular, confluent, and advanced destructive. These are not just academic labels. In the COPDGene study, which tracked outcomes in a large cohort, the mortality risk rose with each step up the scale. Compared with people who had no visible emphysema, those with mild centrilobular emphysema had about 1.7 times the risk of death, moderate centrilobular emphysema carried 2.5 times the risk, and confluent or advanced destructive emphysema pushed the hazard ratio to 5.0 and 4.1 respectively.4PubMed Central. CT-based Visual Classification of Emphysema: Association with Mortality in the COPDGene Study These numbers were adjusted for other factors that affect survival, meaning the emphysema grade itself was independently linked to dying sooner.
So if your CT report says “trace centrilobular emphysema,” you are in a very different situation than someone whose report describes confluent disease. Trace emphysema did not significantly raise mortality in that study. The jump from trace to mild is where the risk becomes real, and it escalates from there. This is why getting a specific grade, not just a yes-or-no diagnosis, is important when talking to your doctor about what to expect.
How Centrilobular Emphysema Differs from Paraseptal Emphysema
CT scans sometimes show centrilobular and paraseptal emphysema in the same person, and readers understandably wonder whether one type is worse than the other. Paraseptal emphysema affects the edges of the lobule, typically near the lung surface, and tends to produce thin-walled cysts along the outer margins of the lung. Centrilobular emphysema, as described above, chews through the center of the lobule and favors the upper lobes.
The clinical evidence suggests centrilobular emphysema is the more serious of the two in terms of long-term outcomes. In a study that followed COPD patients over time, moderate or worse centrilobular emphysema was associated with additional decline in lung function and higher 10-year mortality, while the presence of paraseptal emphysema alone was not.5PubMed. Stronger Associations of Centrilobular Than Paraseptal Emphysema With Longitudinal Changes in Diffusing Capacity and Mortality in COPD One area where paraseptal emphysema may cause more acute trouble is in spontaneous pneumothorax, which is mainly linked to rupture of subpleural blisters or bullae at the lung surface, the territory where paraseptal disease lives.
That said, the two subtypes sometimes progress at similar rates. A retrospective study comparing the two found no significant difference in the yearly change of the overall low-attenuation volume, a common measure of emphysema extent on CT, though there were subtle differences in how the smallest areas of destruction evolved over time.6Journal of Computer Assisted Tomography. Quantitative Computed Tomography Analysis of the Longitudinal Change Between Centrilobular and Paraseptal Emphysema Subtypes: A Retrospective Study The takeaway is that centrilobular emphysema carries the heavier burden on lung function and survival, while paraseptal emphysema poses its own structural risks but is less consistently tied to declining spirometry and mortality.
How Lung Function Declines Over Time
One of the most common questions after a centrilobular emphysema diagnosis is how fast things will get worse. A ten-year follow-up of patients with early emphysema found an average decline in the key lung function measure (FEV1) of about 89 milliliters per year, a rate similar to what is seen in classic COPD across the board.7PubMed. Early emphysema. Ten years’ evolution That study also noted the decline could not be clearly predicted by initial lung function or smoking habits at baseline, which underscores the frustrating variability of the disease. Some people progress slowly; others lose function much faster.
Beyond airflow, centrilobular emphysema has a pronounced effect on the lung’s ability to transfer oxygen into the blood. The diffusing capacity, which measures how efficiently gas crosses from the air sacs into the bloodstream, tends to drop disproportionately in people with emphysema. A study found that disproportionately impaired diffusing capacity was associated with worse symptoms, shorter walking distance, and lower blood oxygen levels in COPD patients with centrilobular emphysema visible on CT.8PubMed. Disproportionally Impaired Diffusion Capacity Relative to Airflow Limitation in COPD This is why some people with emphysema feel more breathless than their spirometry numbers alone would predict: the oxygen-transfer problem can be worse than the airflow numbers suggest.
Flare-ups also become a concern as the disease progresses. In COPD patients, those with more emphysema visible on CT were more likely to experience frequent acute exacerbations, and worsening visual subtypes on imaging tracked with exacerbation frequency.9PubMed. Identification of frequent acute exacerbations phenotype in COPD patients based on imaging and clinical characteristics Exacerbations are not just unpleasant episodes of worsening cough and breathlessness; they accelerate the underlying decline in lung function and are themselves a major driver of hospitalization and death in COPD.
Damage Beyond the Lungs
Centrilobular emphysema is often thought of as a lung disease, but its effects reach further than the chest. One of the most significant complications is what it does to the heart. Even when the total amount of lung tissue destroyed by centrilobular emphysema appears relatively moderate and localized, right ventricular hypertrophy, where the right side of the heart thickens because it is working harder to pump blood through damaged lung vessels, was found in most cases in a pathology study. The researchers showed that this cardiac strain was mainly driven by low oxygen levels and mismatches in how air and blood flow through the lungs, rather than by the sheer volume of tissue destroyed.10Thorax. Parenchymal, bronchiolar, and bronchial measurements in centrilobular emphysema In other words, even a moderate amount of centrilobular emphysema can cause serious cardiac consequences because of the way it disrupts gas exchange.
When emphysema coexists with pulmonary fibrosis, an increasingly recognized overlap syndrome, pulmonary hypertension becomes even more common and more dangerous. In one series of patients with combined pulmonary fibrosis and emphysema, pulmonary hypertension was present in nearly half of patients at diagnosis and over half during follow-up, and its presence was a critical determinant of survival.11European Respiratory Journal. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
There are also effects on the body’s muscles. A study of current smokers, some of whom had centrilobular emphysema visible on CT but no formal COPD diagnosis, found that centrilobular emphysema was associated with smaller chest wall muscles even after accounting for other variables. The researchers interpreted this as a sign that susceptibility to skeletal muscle loss may already be elevated in smokers with centrilobular emphysema before they develop measurable airflow limitation.12PubMed Central. Centrilobular Emphysema Is Associated with Pectoralis Muscle Reduction in Current Smokers without Airflow Limitation Muscle wasting is a well-known feature of advanced COPD, but the fact that it appears this early in the disease process, before spirometry catches it, hints at systemic inflammation or deconditioning pathways that start sooner than most people expect.
Does Quitting Smoking Actually Help?
Yes, and the evidence is unambiguous on this point. A follow-up study that measured emphysema progression on CT found that people who had quit smoking more than five years earlier showed significantly slower rates of emphysema progression compared with current smokers. The difference in lung function decline was also meaningful: current smokers lost about 69 milliliters of FEV1 per year, while long-term quitters lost about 57.5 milliliters per year.13PubMed Central. Rate of progression of CT-quantified emphysema in male current and ex-smokers: a follow-up study That 12-milliliter-per-year difference may sound small in isolation, but compounded over a decade, it translates into meaningfully better lung function and potentially years of additional independence.
Quitting does not reverse the damage already done. The destroyed air sacs stay destroyed. But it slows the rate at which new damage accumulates and reduces the chronic inflammatory burden that drives many of the complications described above. For someone with mild or moderate centrilobular emphysema, quitting smoking is the single most impactful thing they can do to change their trajectory. No medication comes close to matching the benefit of smoking cessation in this disease.
Treatment Options and How Well They Work
Beyond smoking cessation, treatment for centrilobular emphysema falls into the broader COPD toolkit: bronchodilators, pulmonary rehabilitation, supplemental oxygen when needed, and in select cases, surgical or minimally invasive procedures to reduce hyperinflated lung volume.
Bronchodilator response in emphysema is not one-size-fits-all. Research has shown that the distribution pattern of emphysema and even genetics can influence how much benefit a patient gets from inhaled bronchodilators. In one study, patients with upper-lobe-dominant emphysema, the classic centrilobular pattern, had a different bronchodilator response depending on their genetic variation in the beta-2 adrenergic receptor gene. Patients carrying a specific variant showed significantly increased bronchodilator response when their emphysema was upper-dominant but not when it was lower-dominant.14PubMed. ADRB2 gene polymorphism and emphysema heterogeneity can modulate bronchodilator response in patients with emphysema This kind of finding is a step toward personalized treatment, though in practice most patients are still managed with standard bronchodilator regimens regardless of subtype.
For patients with severe, upper-lobe-predominant emphysema and significant hyperinflation, lung volume reduction has been an option for decades. The more recent and less invasive version uses endobronchial valves, small one-way devices placed in the airways to deflate the most damaged lobe and let healthier lung tissue expand. A study comparing endobronchial valve treatment in upper-lobe versus lower-lobe emphysema found that both groups showed clinically meaningful improvements in lung function, exercise capacity, and quality of life at six months, with no significant difference between the two groups and no increase in adverse events for lower-lobe treatment.15Respiration. Comparing Clinical Outcomes in Upper versus Lower Lobe Endobronchial Valve Treatment in Severe Emphysema A key requirement for this procedure is that there be little or no airflow between the targeted lobe and adjacent lobes through side channels, a condition the treatment team checks in advance.
How CT Scans Quantify Severity
If you have had a chest CT and your report mentions percentages or technical measurements, it helps to understand what the radiologist is looking at. The most common automated method counts the percentage of lung area that falls below a specific density threshold, typically around negative 950 Hounsfield units, a cutoff that reliably identifies destroyed tissue.16PubMed Central. Quantitative computed tomography in chronic obstructive pulmonary disease A higher percentage means more of your lung is in the emphysema range. Studies have found strong correlations between these low-attenuation percentages and real-world measures of gas exchange, confirming that the CT numbers are not just academic.17PubMed. Emphysema quantification by combining percentage and size distribution of low-attenuation lung regions
Visual scoring by a radiologist adds context that automated measurements alone can miss. A study combining low-attenuation area measurements with visual subtype classification found that adding clinical information to either method substantially boosted diagnostic accuracy for identifying COPD, with the combined approach reaching very high performance.18PubMed Central. Diagnostic efficacy of visual subtypes and low attenuation area based on HRCT in the diagnosis of COPD This is why many pulmonologists want both the quantitative readout and a radiologist’s visual interpretation when assessing how serious the emphysema is.
Artificial intelligence is beginning to play a role in this space as well. A deep-learning model trained to detect emphysema on low-dose CT screening scans achieved a sensitivity of 88 percent in a balanced test set, with an area under the curve of 0.90 for the best-performing configuration.19PubMed Central. AI-Driven Model for Automatic Emphysema Detection in Low-Dose Computed Tomography Using Disease-Specific Augmentation The practical significance is that emphysema could be flagged automatically during routine lung cancer screening scans, catching it in people who were not specifically being evaluated for COPD. Given that mild centrilobular emphysema already carries a meaningful mortality risk, earlier detection through screening CTs could change outcomes for a lot of people who would otherwise not learn about their emphysema until symptoms forced them to a doctor.
Genetic Susceptibility and Why Some Smokers Get It Worse
Not every smoker develops emphysema, and the ones who do vary enormously in how fast and how severely they are affected. Genetics explains a meaningful share of that variation. Genome-wide association studies have identified multiple genetic regions linked to emphysema patterns on CT. A study using CT-based emphysema measurements found seven genetic loci with significant associations, including regions near genes involved in cell signaling and migration as well as established COPD-susceptibility loci like HHIP and the CHRNA3 nicotinic receptor cluster.20American Journal of Respiratory and Critical Care Medicine. Genome-Wide Association Identifies Regulatory Loci Associated with Distinct Local Histogram Emphysema Patterns
A follow-up genome-wide meta-analysis confirmed many of these signals and added new ones, including a variant in the SERPINA1 gene, the same gene responsible for alpha-1 antitrypsin deficiency, the best-known genetic cause of emphysema.21eLife. Identification of an emphysema-associated genetic variant near TGFB2 with regulatory effects in lung fibroblasts More recently, a study in a Swedish population found three genetic loci associated with emphysema specifically in smokers, with no significant signals in never-smokers, reinforcing the idea that genetic susceptibility often requires the environmental trigger of tobacco smoke to manifest as disease.22PubMed Central. Genome-wide association study of image-based emphysema scoring in the Swedish CArdioPulmonary bioImage Study (SCAPIS) suggests two new risk loci in smokers
For most people, genetic testing beyond alpha-1 antitrypsin screening is not yet part of routine clinical care for emphysema. But these findings help explain why two people with the same smoking history can end up in vastly different places: one with trace emphysema at 70, another with confluent disease and oxygen dependence at 55. The genetic landscape is complex, involving dozens of small-effect variants rather than a single on-off switch, which is why simple “emphysema gene” tests have not emerged.
CT Subtypes Within Centrilobular Emphysema
Even within centrilobular emphysema, not all destruction looks the same under the microscope or on a CT scan. Researchers using CT-pathology comparisons have classified the small areas of destruction into distinct types. Type A lesions are small, round, and well-defined, corresponding mainly to dilated bronchioles. Type B lesions are irregularly shaped and under 5 millimeters, reflecting destruction of the structures just downstream of the bronchioles. Type C lesions are larger, irregular, and represent destruction extending further into the gas-exchange zone. In one study, Type B was the dominant pattern in over half of patients, while Type C dominated in about a quarter.23PubMed Central. Classification of Centrilobular Emphysema Based on CT-Pathologic Correlations This kind of fine-grained classification is still more of a research tool than something you will see on a typical radiology report, but it underscores that centrilobular emphysema is not a single uniform process. Different patients may have different predominant patterns of tissue destruction, which could eventually inform more targeted treatment decisions as the field moves toward precision pulmonology.